Completed PHASE2 INTERVENTIONAL 2-arm NCT01208701

The Effects of Atorvastatin on the Nitrogen Oxide-system in Patients With Type 2 Diabetes and Nephropathy (STAD)

The Effect of Atorvastatin on the NO-system in Patients With Type 2 Diabetes and Nephropathy

Sponsor: Erling Bjerregaard Pedersen

Conditions Cardiovascular Diseases Diabetes Mellitus Nephropathy

Updated 5 times since 2017 Last updated: Aug 19, 2015 Started: May 31, 2010 Primary completion: Jan 31, 2012 Completion: Jan 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Cardiovascular Diseases and Diabetes Mellitus, this trial is completed. The trial is conducted by Erling Bjerregaard Pedersen and has accumulated 5 data snapshots since 2010. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

May 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Erling Bjerregaard Pedersen

Data source: Regional Hospital Holstebro

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Holstebro, Denmark